

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

05 AUG 15 PM 12: 34

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name

Organization **McKenna Long & Aldridge**2. Address ☐ Check if different than previously reportedAddress 1 **1900 K Street, N.W.**Suite **100**City **Washington**State **DC**Zip Code **20006**Country **USA**

3. Principal place of business (if different than line 2)

City

State

Zip Code

Country

State/Zip or Country

4a. Contact Name

Prefix Full Name

Mr. Robert Gillcash

b. Telephone number

(202) 496-7373

c. E-mail

rgillcash@mckennalong.com

5. Senate ID

76913-455

7. Client Name

☐ Self**Novo Nordisk Pharmaceuticals**

6. House ID

36126020**TYPE OF REPORT**8. Year **2005**Midyear (January 1-June 30) ☒

OR

Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☐

Termination Date _____

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**12. Lobbying Firms**

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐\$10,000 or more ☒ ⇒ \$ **140,000**

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐\$10,000 or more ☐ ⇒ \$ _____**14. REPORTING METHOD.** Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
- ☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
- ☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Form CompPrinted Name and Title **Robert Gillcash, Government Relations Senior Advisor**

✓

Registrant Name McKenna Long & AldridgeClient Name Novo Nordisk Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** p information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

Medicare prescription drug benefit

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this i

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
John	Clerici		
David	Schwarz		
Frank	Rapoport		
Alex	Albert		
Brian	Finch		

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Add a page for a different i

Printed Name and Title Robert Gillcash, Government Relations Senior Advisor

LD-2DS (R)

Page 2 of 0